ATF3 Deficiency Exacerbates Ageing‐Induced Atherosclerosis and Clinical Intervention Strategy
Advanced Science · 2025-10 · 12 (37)
DOI: 10.1002/advs.202502249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 11.07.2025. Verfasst von Hao Nie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Key Laboratory of Vascular ageing, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of…. Hauptthemen laut MEDLINE: Activating Transcription Factor 3, Atherosclerosis, Muscle, Smooth, Vascular, Aging. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Technologies Research and Development Program, Innovative Research Group Project of the National Natural Science Foundation of China.
Abstract (Originalsprache)
Vascular smooth muscle cell (VSMC) senescence is a pivotal driver of atherosclerosis (AS), but molecular links to ageing‐related dysfunction are unclear. It is aimed to identify regulators of VSMC senescence and develop clinical interventions for ageing‐related AS. Using single‐cell RNA sequencing of human atherosclerotic carotid arteries and immunofluorescence validation, activating transcription factor 3 (ATF3) is identified as central to VSMC senescence. Mechanistic studies employ SMC‐specific ATF3 knockout mice, CUT&Tag‐seq, RNA/protein interaction assays, and m6A epitranscriptomic analyses. To bridge discovery to therapy, high‐throughput virtual screening is performed for ATF3‐targeting compounds and functionally validated hits. ATF3 deficiency in VSMCs accelerates ageing‐induced AS by promoting senescence. Multi‐omics showed ATF3 activates ATG7, triggering autophagy, while cytoplasmic ATG7 enhances ATF3 nuclear translocation, establishing a positive feedback loop. Ageing increases m6A methylation and decreases the stability of Atf3 mRNA. Terazosin (TZ) diminishes the interaction between YTH N6‐methyladenosine RNA binding protein F2 (YTHDF2) and Atf3 mRNA, helping to preserve Atf3 mRNA stability. TZ is a promising therapeutic strategy for delaying VSMC senescence and preventing AS. ATF3 protects against VSMC senescence and AS by orchestrating autophagy via a novel ATF3‐ATG7 amplification loop. Repurposing TZ to stabilize ATF3 offers a translatable approach to combat ageing‐driven cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, Key Laboratory of Vascular ageing, Ministry of Education, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
- Department of Geriatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P. R. China.
ORCID-Profile: Jinhua Yan
Förderung
- National Natural Science Foundation of China
- Key Technologies Research and Development Program
- Innovative Research Group Project of the National Natural Science Foundation of China
Zitieren
APA
Nie, H., Ji, T., Wan, Z., Huang, J., Li, H., Zou, L., Yang, Z., Li, J., Guan, Y., Ruan, L., Yan, J., & Zhang, C. (2025). ATF3 Deficiency Exacerbates Ageing‐Induced Atherosclerosis and Clinical Intervention Strategy. Advanced Science, 12(37). https://doi.org/10.1002/advs.202502249
Vancouver
Nie H, Ji T, Wan Z, Huang J, Li H, Zou L, et al. ATF3 Deficiency Exacerbates Ageing‐Induced Atherosclerosis and Clinical Intervention Strategy. Advanced Science. 2025;12(37). doi:10.1002/advs.202502249
BibTeX
@article{Nie2025,
author = {Nie, Hao and Ji, Tianyi and Wan, Zixin and Huang, Jie and Li, Han and Zou, Lingjiao and Yang, Zhen and Li, Jiarui and Guan, Yuqi and Ruan, Lei and Yan, Jinhua and Zhang, Cuntai},
title = {ATF3 Deficiency Exacerbates Ageing‐Induced Atherosclerosis and Clinical Intervention Strategy},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {37},
doi = {10.1002/advs.202502249}
}
EUVIMED